DDA Platform Offers Wide Range of Genetoxicity Testing Services to Accelerate Different Phases of Drug Discovery

Recently, DDA platform announced the release of its wide range of genetoxicity testing services to accelerate different phases of drug discovery.

DDA platform, the mature division of Creative Bioarray, whose mission focuses on developing satisfactory services and high quality products in order to promote the research process for drug development. With cutting-edge products and experienced scientists, DDA platform is always devoted to facilitating the investigation of life science researches. Recently, DDA platform announced the release of its wide range of genetoxicity testing services to accelerate different phases of drug discovery.

Genotoxicity testing of new chemical entities is an integral part of the drug development process and is a regulatory requirement before new drug approval. By determining genotoxicity in the early stages of drug discovery rather than during regulatory evaluation, the possibility of late failure can be reduced. Creative Bioarray provides a series of genotoxicity testing (non-GLP) services recommended by regulatory agencies. If there is any positive reaction in the in vitro study, a follow-up in vivo study is usually required for the same endpoint.

In the bacterial reverse mutation test, Salmonella typhimurium and Escherichia coli strains that require amino acids are used to detect mutation points. These mutation points may involve substitution, deletion or addition of one or several base pairs. It detects mutations, restores the mutations present in the tested strain and restores the function of the bacteria to synthesize essential amino acids. Bacterial reverse mutation test offered by DDA platform is fast, cheap and easy to perform, and is usually used as a preliminary screening test for genotoxicity or mutagenicity.

The chromosome aberration test aims to identify the factors that cause chromosome structural aberrations by using cultured mammalian somatic cells (peripheral blood lymphocytes, Chinese hamster ovary cell line (CHO)). After the cell culture is exposed to the test substance, the cells are treated with metaphase blocker, harvested and stained. Then analyze the metaphase cells under a microscope for chromosomal aberrations.

The micronucleus test detects micronuclei in the cytoplasm of interphase cells. This method identifies the cleavage and embryonic activity of cells that undergo cell division during or after exposure to the test substance.

In vitro mammalian cell gene mutation testing measures mutations in thymidine kinase (TK), hypoxanthine guanine phosphoribosyl transferase (HPRT), and xanthine guanine phosphoribosyl transferase (XPRT) transgenes. Commonly used cell lines include L5178Y mouse lymphoma cells, CHO, CHO-AS52 and V79 lines of Chinese hamster cells, and TK6 human lymphoblasts. The mutation frequency is determined by seeding a known number of cells in a medium containing a selection agent to detect mutant cells and seeding them in a medium without a selection agent to determine the cloning efficiency.

In vitro comet test, also known as single cell gel electrophoresis (SCEG) test, is a sensitive method for rapid detection of single-cell DNA damage, including double-strand breaks, single-strand breaks, and alkali-labile sites.

“Creative Bioarray focuses on the use of primary cells from many different tissues and organs for predictive, 3D tissue and cell-based in vitro toxicity assays.” said Hannah Cole, the marketing director of Creative Bioarray, she also claimed, “Our scientists not only provide data but also provide expertise to interpret the generated data. We are committed to assisting scientists in determining whether compounds have the potential to apply in the clinic.”

About DDA platform
As a mature division of Creative Bioarray, DDA platform definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.

Contact Info:
Name: Hannah Cole
Email: Send Email
Organization: Creative Bioarray
Address: Shirley, NY 11967, USA
Phone: 1 631 386 8241
Website: https://dda.creative-bioarray.com/

Release ID: 89054059